A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the Russia
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Conditions: HR+HER2- Advanced Breast Cancer
Interventions: OTHER: Ribociclib|OTHER: Combination chemotherapy
Sponsor: Novartis Pharmaceuticals